Annovis Bio, Inc. (ANVS) NYSE
2.01
+0.07(+3.61%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.01
+0.07(+3.61%)
Currency In USD
| Previous Close | 1.94 |
| Open | 1.8 |
| Day High | 2.01 |
| Day Low | 1.75 |
| 52-Week High | 5.5 |
| 52-Week Low | 1.54 |
| Volume | 3.59M |
| Average Volume | 1M |
| Market Cap | 39.54M |
| PE | -1.18 |
| EPS | -1.71 |
| Moving Average 50 Days | 2.15 |
| Moving Average 200 Days | 2.64 |
| Change | 0.07 |
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference
GlobeNewswire Inc.
Mar 03, 2026 1:00 PM GMT
MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases suc
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease
GlobeNewswire Inc.
Feb 12, 2026 1:00 PM GMT
MALVERN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients
GlobeNewswire Inc.
Dec 18, 2025 9:35 PM GMT
Enrollment will begin in January 2026 Participants will be treated with buntanetap for 36 months The study aims to enroll 500 patients MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a la